| Autor: |
Iturbe-Fernández D; Pneumology Department, Marqués de Valdecilla University Hospital, 39008 Santander, Spain., Pulito-Cueto V; Valdecilla Research Institute (IDIVAL), 39008 Santander, Spain., Mora-Cuesta VM; Pneumology Department, Marqués de Valdecilla University Hospital, 39008 Santander, Spain., Remuzgo-Martínez S; Valdecilla Research Institute (IDIVAL), 39008 Santander, Spain., Ferrer-Pargada DJ; Pneumology Department, Marqués de Valdecilla University Hospital, 39008 Santander, Spain., Genre F; Valdecilla Research Institute (IDIVAL), 39008 Santander, Spain., Alonso-Lecue P; Valdecilla Research Institute (IDIVAL), 39008 Santander, Spain., López-Mejías R; Valdecilla Research Institute (IDIVAL), 39008 Santander, Spain., Atienza-Mateo B; Valdecilla Research Institute (IDIVAL), 39008 Santander, Spain.; Division of Rheumatology, Marqués de Valdecilla University Hospital, 39008 Santander, Spain., González-Gay MA; Medicine and Psychiatry Department, University of Cantabria, 39005 Santander, Spain.; Division of Rheumatology, IIS-Fundación Jiménez Díaz, 28040 Madrid, Spain., Cifrián-Martínez JM; Pneumology Department, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.; Valdecilla Research Institute (IDIVAL), 39008 Santander, Spain. |
| Abstrakt: |
Osteopontin (OPN) is a glycoprotein involved in Th1 and Th17 differentiation, and inflammation and tissue remodeling. OPN is a biomarker of disease activity in patients with autoimmune inflammatory conditions. This study aimed to assess the diagnostic and prognostic value of OPN in interstitial lung diseases (ILDs). Between May 2016 and October 2019, 344 patients with ILD were recruited at the Hospital Universitario Marqués de Valdecilla (Spain) and were prospectively followed-up. This study involved the determination of OPN serum levels by ELISA and OPN RNA expression quantified using qPCR. Six genetic polymorphisms in OPN (rs28357094, rs2853749, rs2853750, rs11728697, rs7695531, and rs1126616) were genotyped using TaqMan assays. OPN serum levels were also assessed in 140 healthy controls. OPN serum levels (median [interquartile range]) were significantly higher in ILD patients than in controls (1.05 [0.75-1.51] ng/mL versus 0.81 [0.65-0.98] ng/mL in healthy controls; p < 0.01). OPN serum levels were inversely correlated with the forced vital capacity. OPN serum levels were also higher in ILD patients who died or underwent lung transplantation when compared with the remaining ILD patients (1.15 [0.80-1.72] ng/mL versus 0.99 [0.66-1.32] ng/mL; p = 0.05). Survival worsened in ILD patients with OPN > 1.03 ng/mL at 1, 3, and 5 years. No statistically significant differences in the genetic frequencies of OPN polymorphisms or the RNA expression were found among the different ILD groups. Elevated levels of OPN in the serum may be a useful indicator in identifying patients with ILD who are more likely to experience poor outcomes. |
